 Xeris Biopharma Holdings NASDAQ:XERS said it has entered into a research collaboration and option agreement with Horizon Therapeutics PLC. Under the terms of the agreement, Xeris will use its proprietary formulation technology platform, XeriJect, to develop an ultra-concentrated, ready-to-use, subcutaneous injection of teprotumumab and Horizon will have an option to license the Xeris technology. 